Connor, Clark & Lunn Investment Management (CC&L)
ICPT

Connor, Clark & Lunn Investment Management (CC&L)’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-126,550
Closed -$2.35M – 1616
2023
Q3 		$2.35M Sell
126,550
-26,350
-17% -$298K 0.01% 572
2023
Q2 		$1.69M Buy
152,900
+7,609
+5% +$106K 0.01% 650
2023
Q1 		$1.95M Buy
145,291
+3,068
+2% +$53.1K 0.01% 558
2022
Q4 		$1.76M Buy
142,223
+6,030
+4% +$85.4K 0.01% 573
2022
Q3 		$1.9M Buy
136,193
+38,157
+39% +$614K 0.01% 507
2022
Q2 		$1.35M Sell
98,036
-8,807
-8% -$141K 0.01% 552
2022
Q1 		$1.74M Sell
106,843
-10,786
-9% -$169K 0.01% 529
2021
Q4 		$1.92M Sell
117,629
-466
-0.4% -$7.86K 0.01% 543
2021
Q3 		$1.75M Sell
118,095
-1,901
-2% -$30.4K 0.01% 546
2021
Q2 		$2.4M Buy
119,996
+8,951
+8% +$177K 0.01% 502
2021
Q1 		$2.56M Buy
+111,045
New +$3.1M 0.01% 500
2015
Q1 		– Sell
-4,300
Closed -$671K – 627
2014
Q4 		$671K Buy
+4,300
New +$794K 0.01% 352

Connor, Clark & Lunn Investment Management (CC&L)'s ICPT Position: Q4 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 126,550 shares — an estimated $2.35M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ICPT in Q4 2014 and held it in 12 quarters. The position peaked at $2.56M in Q1 2021. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 126,550 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $2.35M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2014 and held it in 12 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Intercept Pharmaceuticals, Inc. position peaked at $2.56M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2023, filed 9 Feb 2024.